03.24.22
Nutraceutical ingredient supplier Maypro Group has appointed May Yamada-Lifton as the company’s chief operating officer. Yamada-Lifton will lead a center for operational excellence that will oversee operations for Maypro Group’s subsidiaries, including its global nutraceutical distribution business. Her role will support business leaders in marketing strategy, business innovation through new products and methodologies, and the evaluation and allocation of resources to enable global growth.
“As Maypro enters its 45th year, we are preparing for dramatic growth. Ms. Yamada-Lifton will not only unify our operating businesses in the United States, Japan, and China, but she will introduce best practices in marketing, sales, innovation, and human resources based on her experiences leading Fortune 100 companies and organizations designated as ‘best companies to work for,’” Steve Yamada, Maypro’s founder and chairman, said. “Her ability to leverage data mining, analysis, and forecasting systems will be integral to Maypro’s growth and add value to its customers globally.”
Yamada-Lifton brings 20 years of leadership experience from the pharmaceutical, data science, and finance industries, with roles at companies including Pfizer, SAS, CSL Behring, Celgene, Credit Suisse, and Health Business Partners. Most recently, she was a global account manager for SAS where she supported the COVID-19 statistical footprint for Pfizer. She specializes in utilizing data analysis, forecasting, and system automation to optimize organizational purchasing, sales, and performance.
Yamada-Lifton holds undergraduate degrees from the Massachusetts Institute of Technology (MIT) and the University of Tokyo. She completed her MBA with honors from Columbia Business School.
“I am honored to work with the management team to facilitate Maypro’s growth by implementing management techniques from leading companies while building upon the trust and relationships built over the last 45 years,” Yamada-Lifton said. “The world has reignited its passion for health and wellness and Maypro’s innovative, clinically proven products are poised to improve the health, and therefore happiness, of human beings around the world.”
“As Maypro enters its 45th year, we are preparing for dramatic growth. Ms. Yamada-Lifton will not only unify our operating businesses in the United States, Japan, and China, but she will introduce best practices in marketing, sales, innovation, and human resources based on her experiences leading Fortune 100 companies and organizations designated as ‘best companies to work for,’” Steve Yamada, Maypro’s founder and chairman, said. “Her ability to leverage data mining, analysis, and forecasting systems will be integral to Maypro’s growth and add value to its customers globally.”
Yamada-Lifton brings 20 years of leadership experience from the pharmaceutical, data science, and finance industries, with roles at companies including Pfizer, SAS, CSL Behring, Celgene, Credit Suisse, and Health Business Partners. Most recently, she was a global account manager for SAS where she supported the COVID-19 statistical footprint for Pfizer. She specializes in utilizing data analysis, forecasting, and system automation to optimize organizational purchasing, sales, and performance.
Yamada-Lifton holds undergraduate degrees from the Massachusetts Institute of Technology (MIT) and the University of Tokyo. She completed her MBA with honors from Columbia Business School.
“I am honored to work with the management team to facilitate Maypro’s growth by implementing management techniques from leading companies while building upon the trust and relationships built over the last 45 years,” Yamada-Lifton said. “The world has reignited its passion for health and wellness and Maypro’s innovative, clinically proven products are poised to improve the health, and therefore happiness, of human beings around the world.”
